Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker – a retrospective multicenter study

Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: A multicenter retrospective observational study of 40 patients

“…*Low-dose aspirin was added to prevent thromboembolic risk.y Including methotrexate (n ¼ 2), mycophenolate mofetil (n ¼ 3), azathioprine (n ¼ 2), low-dose interleukin-2 (n ¼ 1).with cardiovascular risk factors or antiphospholipid syndrome.5 No onset or worsening of thalidomideinduced neuropathy (n ¼ 7) was observed. SLE with articular involvement developed in 1 patient with isolated CLE but no renal flare as previously reported 3. Raphael Aitmehdi, MD,a Laurent Arnaud, MD, PhD, b Camille Franc es, MD, a Patricia Senet, MD, a Jean-Benoît Monfort, MD, a Tullia de Risi-Pugliese, MD, a Annick Barbaud, MD, PhD, a Fleur Cohen-Aubart, MD, PhD, c Julien Haroche, MD, PhD, c Micheline Pha, MD, c Miguel Hie, MD, c V eronique Le Guern, MD, d Nathalie Costedoat-Chalumeau, MD, PhD, d Ars ene M ekinian, MD, PhD, e Olivier Fain, MD, PhD, e Alexis Mathian, MD, PhD, c Zahir Amoura, MD, MSc, c and François Chasset, MD, PhD a From the Sorbonne Universit e, a Facult e de m edecine, Service de dermatologie et Allergologie, Hôpital Tenon, Groupement Hospitalier Piti e-Salpêtri ere, c French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M edecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses, Internal Medicine Department, d Cochin Hospital, Referral Center for Rare Autoimmune and Systemic Diseases, Universit e de Paris, SELENA-SLEDAI, Safety of Estrogens in Systemic Lupus Erythematosus National AssessmenteSystemic Lupus Erythematosus Disease Activity Index; SLE, systemic lupus erythematosus.…”

“…To the Editor: Small case series have suggested that lenalidomide may be a promising therapeutic option for severe cutaneous lupus erythematosus (CLE). [1][2][3] The aims of this study were to report the long-term efficacy and safety profile of lenalidomide in patients with CLE with a focus on patients with associated systemic lupus erythematosus (SLE) and potential factors associated with complete response (CR).…”

Brodalumab for the treatment of moderate‐to‐severe plaque‐type psoriasis: a real‐life, retrospective 24‐week experience

“…In 39 patients not responding to secukinumab or ixekizumab, PASI 75, PASI 90 and PASI 100 were achieved by 69%, 44% and 28% of patients, respectively, after 16 weeks of brodalumab treatment using the LOCF assessment method 18 . Brodalumab was also effective in a small retrospective study of 23 psoriasis patients with previous failure to IL17A inhibitors (secukinumab or ixekizumab) 26 . After switching to brodalumab, 47.8% of the patients achieved a PASI 75 response at week 12, which was sustained through week 24.…”

“…Due to its rapid onset of action, efficacy and safety profile, brodalumab is a valuable therapeutic option for patients with psoriasis who require lifelong treatment. However, real‐life studies on brodalumab‐treated patients are limited to case reports or studies with small numbers of participants 22‐28 …”

Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy

“…The results of pivotal trials (AMAGINE-1/2/3) highlighted that previous treatment with anti-IL17 therapies showed no impact on the efficacy of brodalumab. In a real-life setting, a multicentre experience showed the efficacy of brodalumab based on PASI 75 response at week 12 in 11/23 (47.8%) patients with moderate-to-severe psoriasis previously treated with ixekizumab or secukinumab [24]. In an open-label study on 39 patients with moderate-to-severe psoriasis who failed treatment with ixekizumab or secukinumab, achieved, at week 16, 76% of patients treated with brodalumab led to achieving PASI 75, 50% achieved PASI 90, 32% complete remission, and 71% an sPGA 0/1 (71%) [25].…”